Talis Biomedical (TLIS)
(Delayed Data from OTC)
$1.56 USD
-0.14 (-8.24%)
Updated Sep 12, 2024 03:26 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Talis Biomedical Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 5 | 8 | 11 | 4 |
Cost Of Goods | 0 | 8 | 0 | 0 | 0 |
Gross Profit | 2 | -4 | 8 | 11 | 4 |
Selling & Adminstrative & Depr. & Amort Expenses | 69 | 112 | 200 | 102 | 31 |
Income After Depreciation & Amortization | -67 | -115 | -192 | -91 | -27 |
Non-Operating Income | 5 | 2 | 0 | 0 | -1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -62 | -113 | -192 | -91 | -27 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -62 | -113 | -192 | -91 | -27 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -62 | -113 | -192 | -91 | -27 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -66 | -106 | -190 | -90 | -26 |
Depreciation & Amortization (Cash Flow) | 1 | 9 | 2 | 1 | 1 |
Income After Depreciation & Amortization | -67 | -115 | -192 | -91 | -27 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.82 | 1.78 | 1.51 | NA | NA |
Diluted EPS Before Non-Recurring Items | -34.12 | -63.57 | -127.14 | NA | NA |
Diluted Net EPS (GAAP) | -34.12 | -63.57 | -127.14 | -644.38 | NA |
Fiscal Year end for Talis Biomedical Corporation falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.07 | 0.20 | 0.14 | 0.58 |
Cost Of Goods | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
Gross Profit | 0.00 | 0.07 | 0.19 | 0.13 | 0.57 |
SG&A, R&D, and Dept/Amort Expenses | 9.58 | 14.18 | 14.64 | 17.10 | 16.97 |
Income After SG&A, R&D, and Dept/Amort Expenses | -9.58 | -14.11 | -14.45 | -16.97 | -16.40 |
Non-Operating Income | 0.73 | 1.08 | 1.00 | 1.29 | 1.36 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -8.85 | -13.04 | -13.46 | -15.68 | -15.03 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -8.85 | -13.04 | -13.46 | -15.68 | -15.03 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -8.85 | -13.04 | -13.46 | -15.68 | -15.03 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 1.82 | 1.82 | 1.82 | 1.82 | 1.82 |
Diluted EPS Before Non-Recurring Items | -4.86 | -7.15 | -7.39 | -8.62 | -8.27 |
Diluted Net EPS (GAAP) | -4.86 | -7.15 | -7.33 | -8.62 | -8.27 |